Ocugen, Inc. Announces Pricing of $22.5 Million Offering of Common Stock

Rhea-AI Summary

Ocugen (Nasdaq: OCGN) priced an underwritten offering of 15,000,000 shares of common stock at $1.50 per share for gross proceeds of $22.5 million, before commissions and offering expenses.

The offering is expected to close on or about January 22, 2026, subject to customary closing conditions. RTW Investments is leading the financing with participation from new and existing investors, and Oppenheimer & Co. is sole book-running manager. Ocugen said net proceeds will be used for general corporate purposes, capital expenditures, working capital, and general and administrative expenses. The offering is being made under a shelf registration on Form S-3 (File No. 333-278774); a prospectus supplement will be filed with the SEC.

Positive

• Gross proceeds of $22.5 million from the offering
• 15,000,000 shares fully offered by Ocugen (clearly funded financing)
• Financing led by RTW Investments with participation from new and existing investors

Negative

• Issuance of 15,000,000 new shares may dilute existing shareholders
• Proceeds earmarked for general corporate purposes rather than specific projects

News Market Reaction – OCGN

-10.78% 1.8x vol

22 alerts

-10.78% News Effect

+10.4% Peak Tracked

-3.6% Trough Tracked

-$64M Valuation Impact

$531M Market Cap

1.8x Rel. Volume

On the day this news was published, OCGN declined 10.78%, reflecting a significant negative market reaction. Argus tracked a peak move of +10.4% during that session. Argus tracked a trough of -3.6% from its starting point during tracking. Our momentum scanner triggered 22 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $64M from the company's valuation, bringing the market cap to $531M at that time. Trading volume was above average at 1.8x the daily average, suggesting increased trading activity.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Shares offered: 15,000,000 shares Offering price: $1.50 per share Gross proceeds: $22.5 million +1 more

4 metrics

Shares offered 15,000,000 shares Underwritten common stock offering

Offering price $1.50 per share Pricing for new common stock

Gross proceeds $22.5 million Before commissions and expenses

Current price $1.67 Pre-news market price

Market Reality Check

Price: $1.77 Vol: Volume 4,997,772 is below...

normal vol

$1.77 Last Close

Volume Volume 4,997,772 is below the 20-day average of 5,750,189 ahead of the offering news. normal

Technical Price at $1.67, trading above the 200-day MA of $1.16 and about 14.8% below the 52-week high of $1.96.

Peers on Argus

OCGN was down 1.18% while key biotech peers like FDMT (+3.67%), MBX (+8.45%), DS...

OCGN was down 1.18% while key biotech peers like FDMT (+3.67%), MBX (+8.45%), DSGN (+4.30%), and LRMR (+3.90%) moved higher, pointing to a stock-specific reaction to the offering.

Historical Context

5 past events · Latest: Jan 15 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 15	Phase 2 data update	Positive	-13.8%	Positive preliminary 12‑month OCU410 Phase 2 data in GA dry AMD.
Jan 13	Data webcast	Positive	+7.3%	Announcement of webcast to review OCU410 Phase 2 ArMaDa trial data.
Jan 12	Phase 1 results	Positive	+18.7%	Publication of positive Phase 1 GARDian1 OCU410ST trial safety and efficacy data.
Jan 09	Conference presentation	Positive	+0.7%	J.P. Morgan conference presentation and plan for three BLAs over two years.
Dec 10	Conference appearance	Positive	+1.6%	Oppenheimer rare disease summit appearance and discussion of 2026 catalysts.

Pattern Detected

Recent OCGN news has mostly seen price moves align with positive clinical and corporate updates, with one notable divergence on strong Phase 2 data.

Recent Company History

Over the last few months, Ocugen has highlighted multiple clinical and corporate milestones. In December 2025 and January 2026, it shared positive Phase 1 and Phase 2 data for OCU410ST and OCU410, plus plans for up to three BLAs over two years, and conference appearances. Price reactions typically aligned with positive news, except a -13.83% move on strong OCU410 data. Today’s financing follows this period of data-driven momentum and prior capital raises disclosed in filings.

Market Pulse Summary

The stock dropped -10.8% in the session following this news. A negative reaction despite the capital...

Analysis

The stock dropped -10.8% in the session following this news. A negative reaction despite the capital raise fits prior sensitivity to financing and dilution risk. Earlier, an August 2025 registered direct deal produced mixed short-term moves of -1.77% and then +5.03%. With operating losses and going‑concern language in recent filings, investors may have focused on dilution more than balance‑sheet support, leaving room for continued volatility as new shares are absorbed.

Key Terms

underwritten offering, prospectus supplement, registration statement, book-running manager

4 terms

underwritten offering financial

"announced the pricing of its underwritten offering of 15,000,000 shares"

An underwritten offering is when a bank or group of banks agrees to buy all of a company's new shares or bonds and then resell them to outside investors, guaranteeing the company will raise a specific amount of money. It matters to investors because it adds certainty that the funding will close while increasing the number of shares or debt in the market, which can lower the price per share and change each existing owner's ownership percentage—think of a wholesaler buying an entire shipment from a maker before it reaches stores.

prospectus supplement regulatory

"A prospectus supplement relating to and describing the terms of the offering will be filed"

A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

registration statement regulatory

"The offering is being made by Ocugen pursuant to a shelf registration statement"

A registration statement is a formal document that companies file with a government agency to offer new shares of stock to the public. It provides essential information about the company's finances, operations, and risks, helping investors make informed decisions. Think of it as a detailed product description that ensures transparency and trust before buying into a company.

book-running manager financial

"Oppenheimer & Co. is acting as the sole book-running manager for the offering."

A book-running manager is the lead organizer responsible for coordinating a large financial sale, such as issuing new stocks or bonds. They oversee preparing all necessary documents, setting the sale’s price, and finding buyers, much like a concert promoter arranging a major event. Their role matters to investors because they help ensure the offering is successfully sold at the best possible terms.

AI-generated analysis. Not financial advice.

MALVERN, Pa., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the pricing of its underwritten offering of 15,000,000 shares of its common stock at an offering price of $1.50 per share of common stock for gross proceeds of $22.5 million, before deducting commissions and other estimated offering expenses payable by Ocugen. The offering is expected to close on or about January 22, 2026, subject to the satisfaction of customary closing conditions. All of the securities to be sold in the offering are being offered by Ocugen. The financing is being led by RTW Investments, with additional participation from new and existing investors.

Ocugen intends to use the net proceeds from the offering for general corporate purposes, capital expenditures, working capital, and general and administrative expenses.

Oppenheimer & Co. is acting as the sole book-running manager for the offering.

The offering is being made by Ocugen pursuant to a shelf registration statement on Form S-3 (File No. 333-278774) previously filed with the Securities and Exchange Commission (the “SEC”) on April 18, 2024, which became effective on May 1, 2024. The securities may be offered only by means of a prospectus and prospectus supplement that form a part of the registration statement. A prospectus supplement relating to and describing the terms of the offering will be filed with the SEC and will be available on the SEC’s website. When available, copies of the prospectus supplement and the accompanying base prospectus relating to the offering, may be obtained by visiting the SEC’s website at www.sec.gov or by contacting Oppenheimer & Co. Inc. Attention: Syndicate Prospectus Department, 85 Broad Street, 26th Floor, New York, NY 10004, or by telephone at (212) 667-8055, or by email at EquityProspectus@opco.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.

About Ocugen, Inc.

Ocugen, Inc. is a pioneering biotechnology leader in gene therapies for blindness diseases. Our breakthrough modifier gene therapy platform has the potential to address significant unmet medical need for large patient populations through our gene-agnostic approach. Unlike traditional gene therapies and gene editing, Ocugen’s modifier gene therapies address the entire disease—complex diseases that are potentially caused by imbalances in multiple gene networks. Currently we have programs in development for inherited retinal diseases and blindness diseases affecting millions across the globe, including retinitis pigmentosa, Stargardt disease, and geographic atrophy—late stage dry age-related macular degeneration.

Cautionary Statement Regarding Forward Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. Such forward-looking statements within this press release include, without limitation, statements regarding Ocugen’s expectations regarding the timing of the completion of the offering and the anticipated use of proceeds. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from our current expectations, such as market and other conditions. These and other risks and uncertainties are more fully described in our periodic filings with the SEC, including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by applicable law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, changed circumstances or otherwise, after the date of this press release.

Ocugen Contact:

Tiffany Hamilton
AVP, Head of Communications
Tiffany.Hamilton@Ocugen.com

FAQ

How many shares did Ocugen (OCGN) offer in the January 21, 2026 financing?

Ocugen priced an offering of 15,000,000 shares of common stock.

What was the offering price and gross proceeds for Ocugen (OCGN) on January 21, 2026?

The offering price was $1.50 per share for gross proceeds of $22.5 million.

When is the Ocugen (OCGN) offering expected to close?

The offering is expected to close on or about January 22, 2026, subject to customary closing conditions.

Who led the Ocugen (OCGN) financing and who is the manager?

The financing was led by RTW Investments, and Oppenheimer & Co. is the sole book-running manager.

What will Ocugen (OCGN) use the net proceeds from the $22.5M offering for?

Ocugen intends to use net proceeds for general corporate purposes, capital expenditures, working capital, and general and administrative expenses.

Where can investors find the Ocugen (OCGN) prospectus supplement for the offering?

A prospectus supplement will be filed with the SEC and will be available on the SEC website when filed.